1 / 18

Clinical Phase I Trial

Clinical Phase I Trial. Signe Sorup Alex Chaudhuri Sandrine Duron. Objectives. Primary -  To assess the safety and tolerability of one dose of rBCG-Pasteur B vaccine compared to BCG in healthy adults.

riva
Télécharger la présentation

Clinical Phase I Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Phase I Trial Signe Sorup Alex Chaudhuri Sandrine Duron

  2. Objectives Primary -  To assess the safety and tolerability of one dose of rBCG-Pasteur B vaccine compared to BCG in healthy adults. The endpoints will be any local and systemic reactogenicity signs      and symptoms, any derangement in laboratory measures or any report of adverse event  during the first 4 weeks after the vaccination. Secondary - To evaluate the immunogenicity of one dose of rBCG Pasteur B vaccine compared to BCG.     The endpoints will be measured by intracellular cytokine staining on whole blood

  3. Design Randomised Double-blinded BCG controlled (Tice strain) Dose escalating Single center Setting - Denmark (Non-endemic + No routine BCG last 30 years)

  4.      Inclusion criteria • Healthy adults, 20 - 30 years old on the day of trial enrollment • Healthy by medical history + clinical examination • Women -  Non-pregnant, contraception during period of trial including total period of follow-up ( not to commence new OCP during trial) • BMI 18-25 • Written consent

  5.      Exclusion criteria • Evidence / risk of latent TB • Positive Tuberculin Test or Positive Quantiferon (IGRA) GOLD • Prior contact with active pulmonary tuberculosis or in relevant health care setting • Abnormal chest X-ray •  Confounders of immunogenicity endpoints • BCG vaccination history or scar • Other vaccination within the 4 preceding weeks • Significant language barrier

  6. Exclusion criteria - 2 • Safety concerns • HIV positive / other immunosuppression • High risk behaviour for acute HIV infection • Illicit drug abuse • Fever > 37.5 c • Current or recent (one month) acute illness • Chronic disease or medication • Abnormality on Full blood Count/Coagulation/Liver enzymes • Abnormal urinary analysis

  7. Advertisement for volunteers • Focus on students • Student magazines • Campuses • Community center

  8. arm rBCG Pasteur B* Controls (BCG TICE) Number of injections Time of entry Method - schedule Number of subjects Dose (CFU) Number of subjects Dose (CFU) 1 7 5*103 2 5*105 1 Day 0 2 7 5*104 2 5*105 1 Day 40 3 7 5*105 2 5*105 1 Day 80 4 7 5*106 2 5*105 1 Day 120 * TICE BCG strain with overexpression of Ag85A, Ag85B, PPE44 and DA-1

  9. Method - description of the product • No obvious difference between the rBCG Pasteur B and BCG • Reconstituted by the pharmacist • immediately prior to the injection • 0.1 ml of neutral solvent  • Route of administration: intra-dermal 

  10. Adverse events Any untoward medical event that occurs after administration of the injection regardless of whether it is directly attributable to the vaccine or not.

  11. Reactogenicity • Common adverse events usually observed after immunization • Local reaction • Systemic reaction • Usually occur up to 2 - 3 days after immunization Adverse events

  12. According to the FDA guidance toxicity grading scale • Mild/moderate/severe/potentially life-threatening AE • Serious adverse events • Death • Life threatening adverse events • Hospitalisation or prolonged hospitalisation length • Significant disability or incapacity • Congenital abnormality, birth defect, unintentional fetal loss Adverse events

  13. Daily diary formated • Solicited and unsolicited adverse events • Filled by the volunteer •  Case report forms (CRF) • Filled by the physicians (diagnosis/syndroms) • Based on the volunteers diary • Clinical examination • Physician • Pre vaccination • Day 0 (after injection) • Subjects observation for an hour after  the injection • Vital signs monitoring at 30 and 60 minutes post-injection  • Local reactions evaluation at 60 minutes • Day 7, 14, 28 • Biological tests • Hematology/ liver enzymes/ renal function • Pre vaccination • Day 0, 7, 14, 28 Data collection

  14. Serious adverse events declaration • Dedicated phone number • Declaration as soon as possible • to the sponsor • to the institutional review board (IRB)  • Investigation • Suspend further vaccine administration if possibly related to vaccine

  15. Immunogenicity assessment • Intra cellular cytokine staining (flow cytometry) • Total cytokine positive CD4 frequency  • expression of IFN gamma, IL-2, TNF alpha singly or in combination (polyfunctional T cell) • Same with CD8 T cells • Whole blood (frozen after stimulation) and PBMC for a subset of volunteers 

  16. Pre-vaccination 0 7 14 28 42 84 182 Serious adverse event Diary Case-report forms Clinical examination x x x x x Blood sample 10ml 10 ml 10 ml 10 ml 10 ml 10 ml 10 ml 10 ml Biological tests for adverse events x x x x x Immunogenicity x x x x x x x Follow-up schedule

  17. Rate of all adverse event • Rate of adverse events acording to severity • Rate of AE’s possibly attributable to vaccine • Immunological endpoints Endpoints

  18. Environmental and regulatory challenges • Comply with local GMO guideline  • Biohazard facility • Disposal of residual vaccine as medical waste • Drug sensitivity of the new recombinant BCG • Choose  adults instead of infants • phase 1 trial : infants  • issue of Informed consent

More Related